Impact of exacerbations on St George’s Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: http://ginasthmaorg/gina-reports/. 2017.
   Google Scholar
• Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910–917. doi: 10.1136/thx.2010.153643.
   PubMed Web of Science ®Google Scholar
• Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin Exp Allergy 2014;44:212–221. doi: 10.1111/cea.12179.
   PubMed Web of Science ®Google Scholar
• Filipowski M, Bozek A, Kozlowska R, Czyżewski D, Jarzab J. The influence of hospitalizations due to exacerbations or spontaneous pneumothoraxes on the quality of life, mental function and symptoms of depression and anxiety in patients with COPD or asthma. J Asthma 2014;51:294–298. doi: 10.3109/02770903.2013.862543.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New Eng J Med 2009;360:973–984. Epub 2009/03/07. PubMed PMID: 19264686; PubMed Central PMCID: PMCPMC3992367. doi: 10.1056/NEJMoa0808991.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J: J General Pract Airways Group 2007;16:22–27. Epub 2007/02/14. doi: 10.3132/pcrj.2007.00002.
   PubMedGoogle Scholar
• Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract 2014;2:544–552. e1–2. doi: 10.1016/j.jaip.2014.02.011.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, Masa JF, Viejo JL, Jiménez-Ruiz CA, Miravitlles M. Interpretation of quality of life scores from the St George’s Respiratory Questionnaire. Eur Respir J 2002;19:405–413.
   PubMed Web of Science ®Google Scholar
• Quirk FH, Jones PW. Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. Clin Sci (Lond) 1990;79:17–21.
   PubMed Web of Science ®Google Scholar
• Nelsen LM, Kimel M, Murray LT, Ortega H, Cockle SM, Yancey SW, Brusselle G, Albers FC, Jones PW. Qualitative evaluation of the St George’s Respiratory Questionnaire in patients with severe asthma. Respir Med 2017;126:32–38. Epub 2017/04/22. doi: 10.1016/j.rmed.2017.02.021.
   PubMed Web of Science ®Google Scholar
• Nelsen LM, Vernon M, Ortega H, Cockle SM, Yancey SW, Brusselle G, Albers FC, Jones PW. Evaluation of the psychometric properties of the St George’s Respiratory Questionnaire in patients with severe asthma. Respir Med 2017;128:42–49. Epub 2017/06/15. doi: 10.1016/j.rmed.2017.04.015.
   PubMed Web of Science ®Google Scholar
• Albers FC, Mullerova H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma 2017;55:1–9. doi: 10.1080/02770903.2017.1322611.
   Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New Engl J Med 2014;371:1198–1207. doi: 10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390–400. Epub 2017/04/12. doi: 10.1016/s2213-2600(17)30125-x.
   PubMed Web of Science ®Google Scholar
• FDA. Nucala (mepolizumab) Prescribing Information 2015 [December 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125526s004lbl.pdf.
   Google Scholar
• EMA. Nucala (mepolizumab) Summary of Product Characteristics 2015 [December 2018]. Available from: https://ec.europa.eu/health/documents/community-register/2015/20151202133270/anx_133270_en.pdf.
   Google Scholar
• Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des, Dev Ther 2017;Volume 11:3137–3144. doi: 10.2147/DDDT.S150656.
   Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England) 2012;380:651–659. Epub 2012/08/21. doi: 10.1016/s0140-6736(12)60988-x.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373. doi: 10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398–404. Epub 2002/04/09.
   PubMed Web of Science ®Google Scholar
• Jones PW, ST George’s Respiratory Questionnaire Manual. St George's Univeristy of London, 2009. Available from: http://www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf [last Accessed June 2019].
   Google Scholar
• Spencer S, Jones PW, Group GS. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589–593. PubMed PMID: 12832673; PubMed Central PMCID: PMCPMC1746751. doi: 10.1136/thorax.58.7.589.
   PubMed Web of Science ®Google Scholar